Generation Bio Co. (GBIO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Generation Bio Co. (GBIO)
Go deeper and ask any question about GBIO
Company Performance
Current Price
as of Sep 13, 2024$2.60
P/E Ratio
N/A
Market Cap
$173.53M
Description
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGBIO
- Price$2.6+2.77%
Trading Information
- Market Cap$173.53M
- Float73.07%
- Average Daily Volume (1m)94,203
- Average Daily Volume (3m)118,768
- EPS-$2.39
Company
- Revenue$13.17M
- Rev Growth (1yr)364.89%
- Net Income-$20.43M
- Gross Margin69.13%
- EBITDA Margin-499.85%
- EBITDA-$20.45M
- EV$64.63M
- EV/Revenue4.91
- P/EN/A
- P/S13.13